Compare Natera Inc. Common Stock (NTRA) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Verisign, Inc. — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Verisign, Inc. trades at $302.35 (market cap $27.25B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× Verisign, Inc.'s market cap, and Verisign, Inc. pays a 1.07% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Verisign, Inc. for 124 Days on average.
| NTRA | VRSN | |
|---|---|---|
Market Cap | $57.03B | $27.25B |
Volume | 1,131,157 | 709,982 |
Sector | Health | Technology |
52-Week High | $425.64 | $310.00 |
52-Week Low | $179.42 | $211.49 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $56.18B | $28.55B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VeriSign (VRSN) trades at $301.76, down 0.31% with mixed earnings performance. The stock shows bullish technical signals with strong institutional buying and a $348 consensus price target. Recent Q2 2026 results showed 6% revenue growth and 7.7% EPS increase, though Q3 2026 earnings are pending. The company maintains exceptional profitability with 49.77% net margins and robust cash flow generation.
Outlook remains positive with AI-driven domain growth and pending price increases supporting double-digit profit potential. Key risks include antitrust litigation and high valuation multiples. Analyst consensus leans bullish with 60% buy ratings, though insider selling and elevated P/E of 32.73 warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
